A5051502387- DNA Repair Mechanisms
- CAR-T cell therapy research
- Prenatal Screening and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Epigenetics and DNA Methylation
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Polyomavirus and related diseases
- Pluripotent Stem Cells Research
- Autophagy in Disease and Therapy
- Cytomegalovirus and herpesvirus research
- Carcinogens and Genotoxicity Assessment
- CRISPR and Genetic Engineering
- Cytokine Signaling Pathways and Interactions
- Race, Genetics, and Society
- Immunodeficiency and Autoimmune Disorders
- Cancer-related gene regulation
- Acute Lymphoblastic Leukemia research
- RNA modifications and cancer
Stanford University
2022-2025
California Institute for Regenerative Medicine
2024
Stanford Medicine
2024
Hematopoietic stem cell transplantation (HSCT) is the only definitive cure for pediatric acute myeloid leukemia (AML). Despite adjustments in HSCT protocols and improvements supportive care, 30% of high-risk patients who receive as part their therapy still experience disease relapse with high transplant-related mortality. Relapsed AML has a dismal prognosis, novel therapies are needed. To improve upon status quo, would more effectively eliminate relapse-initiating leukemic cells be delivered...
Anti-CD117 monoclonal antibody (mAb) agents have emerged as exciting alternative conditioning strategies to traditional genotoxic irradiation or chemotherapy for both allogeneic and autologous gene-modified hematopoietic stem cell transplantation. Further, these are concurrently being explored in the treatment of mast disorders. Despite promising results animal models more recently patients, short-term long-term effects treatments not been fully explored. We conducted rigorous assessments...
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for patients with many different blood and immune diseases; however, current regimens contain non-specific chemotherapy and/or irradiation conditioning, which carry both short-term long-term toxicities. The use of such agents may be particularly harmful Fanconi anemia (FA), who have genetic mutations resulting in deficiencies DNA repair, leading to increased sensitivity genotoxic agents. mAb-based conditioning has been...
Abstract Fanconi Anemia (FA) is an inherited DNA-repair deficiency caused by mutations in diverse Fanc genes that leads to bone marrow failure and malignancies. FA disease begins at early embryonic stages, while prenatal testing has long been available, no fetal therapies for currently exist. Postnatally, hematologic can be cured through allogeneic hematopoietic stem cell transplantation (HSCT); however, this requires chemotherapy and/or irradiation-based conditioning which amongst various...
Abstract Background Hematopoietic stem cell transplantation (HSCT) is a curative treatment for many diverse blood and immune diseases. However, HSCT regimens currently commonly utilize genotoxic chemotherapy and/or total body irradiation (TBI) conditioning which causes significant morbidity mortality through inducing broad tissue damage triggering infections, graft vs. host disease, infertility, secondary cancers. We previously demonstrated that targeted monoclonal antibody (mAb)-based HSC...
"YIA22-001: Development of hKIT Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure Pediatric Acute Myeloid Leukemia" published on 31 Mar 2022 by National Comprehensive Cancer Network.